STAT

DECEMBER 13, 2023

employers facing surging costs from paying for Novo Nordisk’s Wegovy and similar obesity drugs are hiring virtual health care providers like Teladoc to implement weight-loss management programs , according to Reuters , which spoke with a dozen consultants, pharmacy benefit managers, analysts, and health care providers. … U.S.

Hospitals 269

Hospitals 269

World Pharma News

APRIL 14, 2023

New research shows that several anti-obesity medications could be manufactured and profitability sold worldwide at far lower estimated lower prices compared to their high costs, according to a new study in Obesity, The Obesity Society's (TOS) flagship journal.

61

61

STAT

JUNE 7, 2023

 government will launch a $50 million pilot program to explore how new weight-loss drugs such as Novo Nordisk’s Wegovy can be given to more obese patients outside of specialist services in hospitals , Reuters writes. Have a wonderful day, and please do stay in touch. … The U.K. government The move comes after the U.K.’s

Hospitals 245

Hospitals Vaccines 245

Putting Patients First Blog

MARCH 4, 2024

Guest Blog: Obesity Care Week 2024: Raising Awareness to Break the Stigma of Obesity March 4, 2024 By: Kristal Hartman, Obesity Action Coalition Board Chair Obesity is a complex and multifaceted health issue that affects millions of people worldwide. Obesity is driven by powerful underlying biology, not choice.

Diabetes 50

Diabetes 50

pharmaphorum

FEBRUARY 8, 2022

Novo Nordisk’s new obesity therapy Wegovy has been recommended for routine NHS use by UK cost-effectiveness watchdog NICE, but in a narrower group of patients than is covered by its MHRA-approved label. The 2019 Health Survey for England estimated 28% of adults in England were obese and a further 36% were overweight, according to NICE.

Labelling 105

Labelling Diabetes 105

ALiEM - Pharm Pearls

NOVEMBER 17, 2023

The most common predisposing factors to this condition include obesity, cough, trauma, constipation, or a history of any activity that causes a sudden recurrent increase in pelvic pressure, such as a trip to the trampoline park as was the case in this patient [1]. Evaluation of vulvovaginal bleeding in children and adolescents. Uptodate.com.

250

250

Express Pharma

JANUARY 2, 2024

GLP-1 RAs are recommended in the treatment guidelines by the American Diabetes Association as well as the American Association of Clinical Endocrinology (AACE) Consensus Statement & European Society of Cardiology for type 2 diabetes mellitus patients with co-morbidities, like established atherosclerotic cardiovascular disease and obesity.

Diabetes 111

Diabetes Biosimilars 111

ALiEM - Pharm Pearls

AUGUST 14, 2023

2022] Copyright Images and cases from the Society of Academic Emergency Medicine (SAEM) Clinical Images Exhibit at the 2021 SAEM Annual Meeting | Copyrighted by SAEM 2021 – all rights reserved. Physical Exam Vitals : T 100.4°F; Scleszka Laura, Swan Tricia. October 9, 2020. Can Urine Color Guide Management? online] EMRA.

130

130

ALiEM - Pharm Pearls

DECEMBER 8, 2023

Additionally, cardiovascular co-morbidities, such as obesity, hypertension, and diabetes, can increase the risk. Copyright Images and cases from the Society of Academic Emergency Medicine (SAEM) Clinical Images Exhibit at the 2023 SAEM Annual Meeting | Copyrighted by SAEM 2023 – all rights reserved. 2018 Apr;22(2):353-361.

Diabetes 152

Diabetes 152

STAT

APRIL 24, 2024

One study from the American Society of Health-System Pharmacists found that GLP-1 treatments were a main driver of the increase in overall drug spending by health entities such as pharmacies and hospitals last year. billion, making the drug the top-selling medicine in 2023.

Diabetes 351

Diabetes Hospitals 351

RX Note

JUNE 5, 2023

In obese patients, some clinicians prefer to use an adjusted body weight; the adjustment factor may vary based on practitioner and/or institutional preference. External Links American Cancer Society BC Cancer eviQ National Cancer Institute National Comprehensive Cancer Network Chemotherapy Toxicity Table with Boxed Warnings, 2021

Chemotherapy 52

Chemotherapy Diabetes Hospitals 52

pharmaphorum

AUGUST 11, 2020

“Whilst our treatments will help manage symptoms – and maybe one day offer a cure – we also recognise that these are unsustainable chronic conditions for society. The solution to obesity isn’t just ‘exercise more’. There are various triggers for why obesity happens, and more and more factors are starting to be understood.

Diabetes 110

Diabetes Packaging Communication 110

STAT

APRIL 24, 2024

 One study from the American Society of Health-System Pharmacists found that GLP-1 treatments were a main driver of the increase in overall drug spending by health entities such as pharmacies and hospitals last year. billion, making the drug the top-selling medicine in 2023.

Biosimilars 269

Biosimilars Compounding Diabetes Hospitals 269

pharmaphorum

JUNE 8, 2022

To compound matters, the population demographic most at risk for lack of sleep are the older members of society who are also the most likely to have existing health problems. Research in the UK found that lower productivity due to lack of sleep could be costing the economy up to £40 billion per year. Why is sleep being discussed more?

Compounding 98

Compounding Diabetes Drug Development 98

pharmaphorum

JUNE 25, 2021

Meanwhile, the European Society of Cardiology has called for a more integrated approach to managing CVD and comorbidities, and the NHS has set out a CVD prevention strategy to avert 150,000 heart attacks and strokes over ten years. “I But there are still very high rates of obesity, smoking and inactivity.

Communication 99

Communication Drug Development 99

European Pharmaceutical Review

JULY 5, 2022

There is also strong evidence that suggests being overweight or obese increases the risk of stomach cancer, and some bacterial and viral infections are under investigation for their potential contribution to disease risk. 3 However, it is not yet regulatory approved in the US or EU for treating gastric cancer.

Chemotherapy 82

Chemotherapy Dosage Labelling Compounding 82

RX Note

MAY 31, 2023

Introduction In 2017, the Malaysian Diabetes Educators Society published the Forum for Injection Technique Malaysia (FIT-MY) to provide evidence-based injection technique recommendations for people with diabetes mellitus who use injectable therapy in their daily management. Moreover, they are usually better tolerated.

Diabetes 88

Diabetes Dosage 88

The Guardian - Pharmaceutical Industry

MAY 14, 2024

Studies show active ingredient semaglutide can reduce the risk of heart attack, improve fertility and help treat diabetes It is a drug that has dominated headlines, first as a medication for type 2 diabetes, then as a weight-loss aid.

Diabetes 82

Diabetes 82

ALiEM - Pharm Pearls

OCTOBER 6, 2023

C; BP 138/75; HR 75; RR 16; O2 sat 96% General : WDWN obese male, A/O x4, in mild distress Abdomen : Soft, nondistended, normoactive bowel sounds, no organomegaly. Risk factors include obesity, BPH, and male sex. He claims intermittent constipation, denies any trauma, and is a truck driver by trade. J Surg Case Rep.

169

169

The Guardian - Pharmaceutical Industry

JANUARY 6, 2024

The Bedfordshire town is one of the UK’s worst spots for obesity , with one hospital admission linked to weight for every 20 residents in 2022. McDonald’s is busy with shoppers, while chains from Subway to German Doner Kebab are opening their doors for the approaching army of hungry stomachs.

Hospitals 87

Hospitals Diabetes 87

The Thyroid Pharmacist

OCTOBER 7, 2022

The majority of the studies to date have come to the conclusion that those with diabetes, high blood pressure, and obesity can benefit from using stevia. Sugar consumption, metabolic disease and obesity: The state of the controversy. Stevia, Nature’s Zero-Calorie Sustainable Sweetener: A New Player in the Fight Against Obesity.

Diabetes 95

Diabetes Immunity Immunization Labelling 95

The Guardian - Pharmaceutical Industry

JULY 8, 2023

Observer investigation raises concerns about the influence of drugs companies in shaping patient care in services that use their products Pharmaceutical giants are pouring tens of millions of pounds into struggling NHS services – including paying the salaries of medical staff and funding the redesign of patient treatment – as they seek to boost drug (..)

Diabetes 99

Diabetes 99

The Guardian - Pharmaceutical Industry

APRIL 9, 2023

A lifestyle approach developed by Dr David Unwin shows benefits that could have significant health implications A red-brick surgery in the seaside resort of Southport in the north-west of England is on the frontline of one of the biggest questions facing the NHS: what’s the best fix for our growing obesity crisis?

Diabetes 98

Diabetes 98

The Guardian - Pharmaceutical Industry

APRIL 30, 2023

But healthcare professionals fear it ignores the underlying socioeconomic causes Like many GPs around the UK, Semiya Aziz has grown accustomed to seeing children as young as four or five who are obese.

95

95

The Guardian - Pharmaceutical Industry

JANUARY 31, 2024

Market value of Danish drugmaker behind Wegovy and Ozempic tops $500bn as demand soars Novo Nordisk shares hit a record high after the Danish company reported soaring sales of its obesity and diabetes drugs Wegovy and Ozempic, pushing its market value past $500bn and cementing its position as Europe’s most valuable company.

Diabetes 65

Diabetes 65

The Guardian - Pharmaceutical Industry

JANUARY 25, 2024

Mounjaro will come in a four-dose device known as a KwikPen for people with type 2 diabetes or obesity A new weight loss injection will be available in the UK within weeks to treat thousands of patients with type 2 diabetes or obesity, after the medicines watchdog became the first major regulator in the world to greenlight the drug in a more convenient (..)

Diabetes 57

Diabetes Pharmaceutical Companies Pharmaceutical Companies 57

The Guardian - Pharmaceutical Industry

APRIL 30, 2023

Department of Health asks watchdog to assess effectiveness of giving semaglutide to obese youngsters aged 12 to 17 Children as young as 12 in England could be given weight-loss injections on the NHS after the government asked medical watchdog Nice to assess the potential benefits of prescribing them to under-18s. Continue reading.

74

74

The Guardian - Pharmaceutical Industry

NOVEMBER 2, 2023

Novo Nordisk says it struggling to keep up with demand after becoming Europe’s most valuable company Business live – latest updates The maker of blockbuster weight-loss drug semaglutide has reported a steep rise in sales and profits as health systems around the world rush to use it to tackle obesity.

Diabetes 54

Diabetes Pharmaceutical Companies Pharmaceutical Companies 54

pharmaphorum

JANUARY 23, 2023

It costs society, as well. The real impact on society and the morale of health systems […] We need to change our lifestyle trajectory right now.” For some, a pill is a perfect solution, but obesity is a complicated condition. Many policies in obesity management have failed. A root-and-branch review is needed.

Diabetes 98

Diabetes 98

The Guardian - Pharmaceutical Industry

APRIL 25, 2023

A boom in injectable weight-loss drugs, such as Wegovy from the Danish pharmaceutical giant Novo Nordisk, a biological type 2 diabetes medication containing semaglutide, has promised to revolutionise obesity treatment in recent months.

Diabetes 69

Diabetes Vaccines 69

The Guardian - Pharmaceutical Industry

FEBRUARY 20, 2023

It’s a prescription drug aimed at helping people with obesity lose weight, but some argue it doesn’t tackle the root cause Clips: BBC, abc7NY Continue reading.

65

65

The Guardian - Pharmaceutical Industry

MARCH 11, 2023

Websites appear to be defying a UK ban on advertising prescription drugs by urging customers to register their interest in the new weight-loss injection As controversy raged about the new weight loss drug approved for use on the NHS , retail chain Superdrug was last week urging customers to register interest in the injection.

66

66

The Guardian - Pharmaceutical Industry

AUGUST 8, 2023

Wegovy manufacturer says five-year study found drug reduced major cardiovascular events by 20% in overweight or obese people The weight-loss jab Wegovy can reduce the risk of major cardiovascular events by 20% in people who are overweight or obese, the company behind the drug says.

54

54

The Guardian - Pharmaceutical Industry

MARCH 18, 2023

Pharmaceutical company behind blockbuster diet jab Wegovy confronts crises on multiple fronts, amid scrutiny of UK activities The maker of slimming jab Wegovy was facing crises on multiple fronts this weekend, with the UK medicines regulator announcing a review of its operations at the same time as an investigation is under way into the approval of (..)

Pharmaceutical Companies 60

Pharmaceutical Companies Pharmaceutical Companies 60

The Guardian - Pharmaceutical Industry

MARCH 16, 2023

Novo Nordisk found to be in breach of ABPI code of practice over sponsored weight-loss courses that promoted its medicines The company behind the slimming jab Wegovy has been suspended from the UK’s pharmaceutical trade association after a row over sponsored weight-loss courses that promoted its medicines.

51

51

The Guardian - Pharmaceutical Industry

APRIL 13, 2023

I’ve never been thin.

Pharmaceutical Companies 75

Pharmaceutical Companies Pharmaceutical Companies 75

pharmaphorum

AUGUST 9, 2022

This is being driven by an ageing population but will only increase the pressure on society to find better treatments and to better understand the progress of the disease. Research published this year suggests that the incidence of Europeans dying from cancer is likely to increase by 32% in 2040, compared to 2020.

Drug Development 110

Drug Development 110